131 related articles for article (PubMed ID: 37154765)
21. Updated chemical scaffolds of ABCG2 inhibitors and their structure-inhibition relationships for future development.
Moinul M; Amin SA; Jha T; Gayen S
Eur J Med Chem; 2022 Nov; 241():114628. PubMed ID: 35944339
[TBL] [Abstract][Full Text] [Related]
22. Human ABCB1 (P-glycoprotein) and ABCG2 mediate resistance to BI 2536, a potent and selective inhibitor of Polo-like kinase 1.
Wu CP; Hsiao SH; Sim HM; Luo SY; Tuo WC; Cheng HW; Li YQ; Huang YH; Ambudkar SV
Biochem Pharmacol; 2013 Oct; 86(7):904-13. PubMed ID: 23962445
[TBL] [Abstract][Full Text] [Related]
23. Metabolism-guided development of Ko143 analogs as ABCG2 inhibitors.
Zhu J; Lei S; Lu J; Hao Y; Qian Q; Devanathan AS; Feng Z; Xie XQ; Wipf P; Ma X
Eur J Med Chem; 2023 Nov; 259():115666. PubMed ID: 37482017
[TBL] [Abstract][Full Text] [Related]
24. A combo-strategy to improve brain delivery of antiepileptic drugs: Focus on BCRP and intranasal administration.
Gonçalves J; Silva S; Gouveia F; Bicker J; Falcão A; Alves G; Fortuna A
Int J Pharm; 2021 Jan; 593():120161. PubMed ID: 33307160
[TBL] [Abstract][Full Text] [Related]
25. Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration.
Tang SC; Lagas JS; Lankheet NA; Poller B; Hillebrand MJ; Rosing H; Beijnen JH; Schinkel AH
Int J Cancer; 2012 Jan; 130(1):223-33. PubMed ID: 21351087
[TBL] [Abstract][Full Text] [Related]
26. Double-transduced MDCKII cells to study human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) interplay in drug transport across the blood-brain barrier.
Poller B; Wagenaar E; Tang SC; Schinkel AH
Mol Pharm; 2011 Apr; 8(2):571-82. PubMed ID: 21309545
[TBL] [Abstract][Full Text] [Related]
27. P-gp/ABCB1 exerts differential impacts on brain and fetal exposure to norbuprenorphine.
Liao MZ; Gao C; Shireman LM; Phillips B; Risler LJ; Neradugomma NK; Choudhari P; Prasad B; Shen DD; Mao Q
Pharmacol Res; 2017 May; 119():61-71. PubMed ID: 28111265
[TBL] [Abstract][Full Text] [Related]
28. Tetrahydrocannabinol and Its Major Metabolites Are Not (or Are Poor) Substrates or Inhibitors of Human P-Glycoprotein [ATP-Binding Cassette (ABC) B1] and Breast Cancer Resistance Protein (ABCG2).
Chen X; Unadkat JD; Mao Q
Drug Metab Dispos; 2021 Oct; 49(10):910-918. PubMed ID: 34326138
[TBL] [Abstract][Full Text] [Related]
29. HM30181 Derivatives as Novel Potent and Selective Inhibitors of the Breast Cancer Resistance Protein (BCRP/ABCG2).
Köhler SC; Wiese M
J Med Chem; 2015 May; 58(9):3910-21. PubMed ID: 25855895
[TBL] [Abstract][Full Text] [Related]
30. [(18)F]FDG is not transported by P-glycoprotein and breast cancer resistance protein at the rodent blood-brain barrier.
Wanek T; Traxl A; Bankstahl JP; Bankstahl M; Sauberer M; Langer O; Kuntner C
Nucl Med Biol; 2015 Jul; 42(7):585-9. PubMed ID: 25823393
[TBL] [Abstract][Full Text] [Related]
31. Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar.
Tang SC; Nguyen LN; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
Int J Cancer; 2014 Mar; 134(6):1484-94. PubMed ID: 24037730
[TBL] [Abstract][Full Text] [Related]
32. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.
Shi Z; Peng XX; Kim IW; Shukla S; Si QS; Robey RW; Bates SE; Shen T; Ashby CR; Fu LW; Ambudkar SV; Chen ZS
Cancer Res; 2007 Nov; 67(22):11012-20. PubMed ID: 18006847
[TBL] [Abstract][Full Text] [Related]
33. Abcc4 together with abcb1 and abcg2 form a robust cooperative drug efflux system that restricts the brain entry of camptothecin analogues.
Lin F; Marchetti S; Pluim D; Iusuf D; Mazzanti R; Schellens JH; Beijnen JH; van Tellingen O
Clin Cancer Res; 2013 Apr; 19(8):2084-95. PubMed ID: 23461902
[TBL] [Abstract][Full Text] [Related]
34. The Inhibitor Ko143 Is Not Specific for ABCG2.
Weidner LD; Zoghbi SS; Lu S; Shukla S; Ambudkar SV; Pike VW; Mulder J; Gottesman MM; Innis RB; Hall MD
J Pharmacol Exp Ther; 2015 Sep; 354(3):384-93. PubMed ID: 26148857
[TBL] [Abstract][Full Text] [Related]
35. The Pim kinase inhibitor SGI-1776 decreases cell surface expression of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and drug transport by Pim-1-dependent and -independent mechanisms.
Natarajan K; Bhullar J; Shukla S; Burcu M; Chen ZS; Ambudkar SV; Baer MR
Biochem Pharmacol; 2013 Feb; 85(4):514-24. PubMed ID: 23261525
[TBL] [Abstract][Full Text] [Related]
36. "Effect of the drug transporters ABCB1, ABCC2, and ABCG2 on the disposition and brain accumulation of the taxane analog BMS-275,183".
Marchetti S; Pluim D; Beijnen JH; Mazzanti R; van Tellingen O; Schellens JH
Invest New Drugs; 2014 Dec; 32(6):1083-95. PubMed ID: 25078948
[TBL] [Abstract][Full Text] [Related]
37. Hedgehog pathway inhibitor HhAntag691 is a potent inhibitor of ABCG2/BCRP and ABCB1/Pgp.
Zhang Y; Laterra J; Pomper MG
Neoplasia; 2009 Jan; 11(1):96-101. PubMed ID: 19107236
[TBL] [Abstract][Full Text] [Related]
38. Potent and selective inhibitors of breast cancer resistance protein (ABCG2) derived from the p-glycoprotein (ABCB1) modulator tariquidar.
Kühnle M; Egger M; Müller C; Mahringer A; Bernhardt G; Fricker G; König B; Buschauer A
J Med Chem; 2009 Feb; 52(4):1190-7. PubMed ID: 19170519
[TBL] [Abstract][Full Text] [Related]
39. In vivo characterization of [
Kannan P; Füredi A; Dizdarevic S; Wanek T; Mairinger S; Collins J; Falls T; van Dam RM; Maheshwari D; Lee JT; Szakács G; Langer O
Eur J Nucl Med Mol Imaging; 2020 Jul; 47(8):2026-2035. PubMed ID: 31729540
[TBL] [Abstract][Full Text] [Related]
40. Bioluminescent imaging of drug efflux at the blood-brain barrier mediated by the transporter ABCG2.
Bakhsheshian J; Wei BR; Chang KE; Shukla S; Ambudkar SV; Simpson RM; Gottesman MM; Hall MD
Proc Natl Acad Sci U S A; 2013 Dec; 110(51):20801-6. PubMed ID: 24297888
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
